Feed CDIX
Summary
28 / 100 · Bulios Score
Valuation 100Growth -Profitability 20Quality 4Debt 7Stability 0
What speaks for it
- Revenue grew by 42% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
2018
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 42% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $10.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $217.7K
Debt $23.1M
Free cash flow over 12 months -$2.77M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Healthcare Segment 100%
By region
- Others 100%
Healthcare Segment brings in 100% of revenue.
Segments in detail